Strong US sales momentum may drive further gains for Zydus Lifesciences

Market share gains in the Indian market and margin expansion are other positives

Ram Prasad Sahu
Last Updated at January 17, 2023 22:43 IST

Cadila Healthcare changes name to Zydus Lifesciences Limited

The y-o-y growth was driven by market share gains in key therapies such as cardiovascular, gastrointestinal, respiratory and gynecology

The stock of pharmaceutical major Zydus Lifesciences is up about 10 per cent from its low towards the end of November, even after considering the correction seen in the past few sessions. Brokerages are positive on the stock, given traction for its key products in the US market, new limited-competition drug launches, regulatory clearance for the Moraiya facility and market share gains in the domestic market.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

MONTHLY

₹ 249

Select

ANNUAL

₹ 1799

Select

Best Offer

SMART ANNUAL

₹ 1499

₹ 1799

Opt for auto renewal and save Rs 300

Select

What you get on Business Standard Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Pick your 5 favourite companies, get a daily email with all news updates on them.
26 years of website archives.
Preferential invites to Business Standard events.